Search

Your search keyword '"Cervarix (Vaccine)"' showing total 44 results
Start Over Descriptor "Cervarix (Vaccine)" Topic papillomavirus infections
44 results on '"Cervarix (Vaccine)"'

1. Human papillomavirus vaccines: WHO position paper (2022 update)/ Vaccins contre les papillomavirus humains: note de synthese de l'OMS (mise a jour de 2022)

Subjects
World Health Organization, Cervarix (Vaccine), Diseases, Vaccines, Papillomavirus infections, Health policy, Vaccination, Medical policy
Abstract

Introduction In accordance with its mandate to provide normative guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers (1) on vaccines and [...]

Published
2022

3. Supply Of Human Papillomavirus Vaccine- Cervarix Vaccine

Subjects
Papillomaviruses, Papillomavirus infections, Vaccines, Business, international, Cervarix (Vaccine)
Abstract

Tenders are invited for Supply of Human Papillomavirus Vaccine- Cervarix Vaccine. Tender Category : Goods OpeningDate : Jul 17 2023 10:30AM Major organization : South Western Railway Address : Swr-central-hosp-stores/south [...]

Published
2023

4. HPV vax unmasks cervical lesions from non-vax strains

Author

Otto, M. Alexander

Subjects
Merck & Company Inc., Cervarix (Vaccine), Vaccines, Papillomavirus infections, Vaccination, Pharmaceutical industry
Abstract

Vaccines against human papillomavirus have been hailed as a success: They have been shown to decrease the incidence of cervical lesions associated with the HPV types that are in the [...]

Published
2022

5. GSK's HPV vaccine Cervarix approved in China for girls aged 9 to 14

Subjects
Cancer -- Prevention, Papillomavirus infections, Cervical cancer, Vaccines, General interest, News, opinion and commentary, Cervarix (Vaccine)
Abstract

London: GSK PLC has issued the following press release: GSK PLC on Friday said China's National Medical Products Administration has approved the use of its HPV vaccine Cervarix for girls [...]

Published
2022

6. Global Advisory Committee on Vaccine Safety, 11-12 December 2013/Comite consultatif mondial de la Securite vaccinale, 11-12 decembre 2013

Subjects
Australia. Therapeutic Goods Administration -- Safety and security measures, Cervarix (Vaccine), Rota Teq (Vaccine), Rotarix (Vaccine), Safety and security measures, Influenza vaccines, Papillomavirus infections, Influenza, Vaccination
Abstract

The Global Advisory Committee on Vaccine Safety (GACVS), an expert clinical and scientific advisory body, was established by WHO to provide independent, scientifically rigorous advice on vaccine safety issues of [...]

Published
2014

7. LATEST COMPANY NEWS

Subjects
Pfizer Inc., Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, Eisai Company Ltd., United States. Food and Drug Administration, United States. Supreme Court, European Union. European Commission, Cervarix (Vaccine), Polivy (Medication), Advair Diskus (Medication), Vaccines, Papillomavirus infections, Vincristine, Dolutegravir, Antidepressants, Hallucinogenic drugs, Cemiplimab
Abstract

London World - Europe's first psychedelic drugs research lab is coming to London - 29/5/2022 Europe's first commercial facility for clinical trials of psychedelic drugs is set to open in [...]

Published
2022

8. Disease Analysis: Human Papillomavirus (HPV) Vaccines

Subjects
Merck & Company Inc. -- Forecasts and trends, Antigens, Vaccines, Papillomavirus, Papillomavirus infections, Vaccination, Pharmaceutical industry -- Forecasts and trends, Diseases, Market trend/market analysis, General interest, News, opinion and commentary, Cervarix (Vaccine)
Abstract

NEW YORK: Reportlinker has issued the following press release: Latest key takeaways Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade. There are currently three [...]

Published
2020

9. Disease Analysis: Human Papillomavirus (HPV) Vaccines

Subjects
Merck & Company Inc. -- Forecasts and trends, Vaccination, Papillomaviruses, Papillomavirus infections, Antigens, Vaccines, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, News, opinion and commentary, Cervarix (Vaccine)
Abstract

NEW YORK, Feb. 7, 2020 /PRNewswire/ -- Latest key takeaways Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade. There are currently three approved vaccines [...]

Published
2020

10. Cervical Cancer Treatment Market Size Worth USD 10.6 Billion by 2025: Grand View Research, Inc

Subjects
Cancer treatment, Vaccines -- Statistics, Cervical cancer, Papillomavirus infections, Cancer research, Generic drugs -- Statistics, Carboplatin -- Statistics, Squamous cell carcinoma, Angiogenesis inhibitors, Adenocarcinoma, Carcinoma, Cell differentiation, Anthracyclines, Business, News, opinion and commentary, Cervarix (Vaccine), Avastin (Medication)
Abstract

SAN FRANCISCO, January 16, 2019 /PRNewswire/ -- The global https://www.grandviewresearch.com/industry-analysis/cervical-cancer-treatment-market?utm_source=prnewswire.com&utm_medium=referral&utm_campaign=PRN_Jan16_Cervical_Cancer_Treatment_RD1&utm_content=Content size is expected to reach USD 10.6 billion by 2025, according to a new report by Grand View Research, Inc. [...]

Published
2019

11. GlaxoSmithKline partners with Alibaba for China HPV vaccine market grab

Subjects
Merck & Company Inc., Vaccines, Cervical cancer, Papillomavirus infections, Vaccination, Pharmaceutical industry, Business, international, Cervarix (Vaccine)
Abstract

GlaxoSmithKlines Cervarix is losing to Mercks Gardasil in the U.S. and Europe, but it hopes to win some scores from China. To do that, it has formed an alliance with [...]

Published
2017

12. Fewer HPV jabs provide equal protection

Subjects
Cervarix (Vaccine), Papillomavirus infections, Equal protection, Equality before the law
Abstract

HPV vaccination with two doses of Cervarix, or even just one, may provide as much protection as three doses, a US study suggests. In the trial, researchers from the US [...]

Published
2011

13. Pharmacology Update: Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (Cervarix™)

Subjects
Vaccines, Antigens, Medical research, Medicine, Experimental, Papillomavirus infections, Pharmacology, Papillomaviruses, Health, Cervarix (Vaccine)
Abstract

Pharmacology Update Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (Cervarix.sup.™) By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD. Dr. Elliott is Chair, Formulary Committee, Northern [...]

Published
2010

14. Education: Journals Club - HPV vaccine

Subjects
Cervarix (Vaccine), Vaccines, Papillomavirus infections, Hydroxides
Abstract

Curriculum statement 10.1 women's health and 11 sexual health Key trials - A phase III trial of the bivalent HPV vaccine has shown that efficacy against CIN2+ associated with HPV-16 [...]

Published
2010

15. Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (Cervarix™)

Subjects
Vaccines, Antigens, Medical research, Medicine, Experimental, Papillomavirus infections, Papillomaviruses, Health, Cervarix (Vaccine)
Abstract

Pharmacology Update Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (Cervarix.sup.™) By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD. Dr. Elliott is Chair, Formulary Committee, Northern [...]

Published
2009

16. Global Cervical Cancer Vaccine Market to Cross US$ 1.6 billion by 2020 Says Pharmaion

Subjects
Merck & Company Inc., GlaxoSmithKline PLC, Cancer vaccines, Cervical cancer, Papillomavirus infections, Pharmaceutical industry, Biological products industry, Business, News, opinion and commentary, Cervarix (Vaccine)
Abstract

BURNABY, Canada, December 3, 2015 /PRNewswire/ -- Growing prevalence of cervical cancer coupled with favorable government initiatives to drive global cervical cancer vaccine market through 2020 According to recently published [...]

Published
2015

17. BENEFIT OF FEWER THAN THREE DOSES OF HPV VACCINE REPORTED

Subjects
United States. National Cancer Institute, Vaccines, Papillomavirus infections, News, opinion and commentary, Cervarix (Vaccine)
Abstract

BETHESDA, MD -- The following information was released by the National Cancer Institute (NCI): Results of a combined analysis of data from two independent trials of the human papillomavirus (HPV) [...]

Published
2015

20. Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Subjects
Papillomaviruses, Papillomavirus infections, Vaccines, Business, Business, international, Cervarix (Vaccine)
Abstract

M2 PRESSWIRE-July 4, 2014-: Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022 (C)1994-2014 M2 COMMUNICATIONS RDATE:04072014 Dublin - Research and Markets (http://www.researchandmarkets.com/research/cwp43c/cervarix) has announced the addition [...]

Published
2014

21. United Kingdom : GSK CervarixA two-dose schedule receives European marketing authorisation

Subjects
Papillomavirus infections, Cervical cancer, Vaccines, Marketing, Business, international, Cervarix (Vaccine)
Abstract

GlaxoSmithKline (GSK) announced today that the European Commission has granted marketing authorisation for its cervical cancer vaccine Cervarixà Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant as a two-dose [...]

Published
2013

23. GSK announces data to support CervarixA(r) two-dose schedule for the prevention of cervical cancer in 9-14 year old girls

Subjects
Papillomavirus infections, Cervical cancer, Vaccines, Business, Business, international, Cervarix (Vaccine)
Abstract

M2 PRESSWIRE-November 4, 2013-: GSK announces data to support CervarixÂ(r) two-dose schedule for the prevention of cervical cancer in 9-14 year old girls(C)1994-2013 M2 COMMUNICATIONS RDATE:04112013 London UK -- GlaxoSmithKline [...]

Published
2013

24. GSK: Hot Stocks

Subjects
Papillomavirus infections, Vaccines, News, opinion and commentary, Cervarix (Vaccine)
Abstract

Nov 04, 2013 (TheFlyOnTheWall.com via COMTEX) -- 09:36 EDT GlaxoSmithKline says data supports Cervarix two-dose schedule for young girls - GlaxoSmithKline announced the results of a Phase III study of [...]

Published
2013

26. A new brand of HPV vaccine to be introduced from September 2012

Subjects
Cancer -- Prevention, Papillomavirus infections, Cervical cancer, Vaccines, Cancer vaccines, Business, Business, international, Cervarix (Vaccine)
Abstract

M2 PRESSWIRE-February 28, 2012-: A new brand of HPV vaccine to be introduced from September 2012(C)1994-2012 M2 COMMUNICATIONS RDATE:27022012 Isle of Man launched the Human Papillloma Virus (HPV) vaccination programme [...]

Published
2012

27. Data published in The Lancet Oncology support high efficacy previously demonstrated by Cervarix (HPV 16 and 18 vaccine) against precancerous cervical lesions caused by HPV 16 and 18 and also efficacy against certain other cancer-causing HPV types

Subjects
Papillomavirus infections, Cervical cancer, Vaccines, Business, Chemicals, plastics and rubber industries, Cervarix (Vaccine)
Abstract

An analysis published in The Lancet Oncology reinforces previous findings showing that GlaxoSmithKline's Cervarix, provided protection against advanced precancerous lesions (CIN3+), above that expected from a vaccine that protects against [...]

Published
2011

28. Data published in The Lancet Oncology support high efficacy previously demonstrated by CervarixA(r) (HPV 16 and 18 vaccine) against precancerous cervical lesions caused by HPV 16 and 18 and also efficacy against certain other cancer-causing HPV types

Subjects
Cancer -- Prevention, Papillomavirus infections, Cervical cancer, Cancer vaccines, Business, Business, international, Cervarix (Vaccine)
Abstract

M2 PRESSWIRE-November 9, 2011-: Data published in The Lancet Oncology support high efficacy previously demonstrated by CervarixÂ(r) (HPV 16 and 18 vaccine) against precancerous cervical lesions caused by HPV 16 [...]

Published
2011

29. Cervarix offers excellent protection for Japanese women as well: Prof Konno

Subjects
Women, Papillomavirus infections, Business, Chemicals, plastics and rubber industries, Cervarix (Vaccine)
Abstract

Prof Konno from Jichi Medical University Saitama Medical Center, Department of Gynecology has disclosed positive findings from the final analysis of data from the phase IIb HPV-032 clinical study on [...]

Published
2010

30. ACIP SUPPORTS 'PERMISSIVE USE,' BUT NOT ROUTINE USE, OF GARDASIL IN MALES

Subjects
Merck & Company Inc., Cervarix (Vaccine), Papillomavirus infections, Vaccines, Warts, Pharmaceutical industry, News, opinion and commentary, Diseases
Abstract

Leawood, KS -- The following information was released by the American Academy of Family Physicians: The CDC's Advisory Committee on Immunization Practices, or ACIP, has recommended against the routine use [...]

Published
2009

31. Glaxo's Cervarix Shows Promise

Subjects
GlaxoSmithKline PLC, Pharmaceutical industry, Papillomavirus infections, Cervical cancer, Personal finance, Cervarix (Vaccine)
Abstract

Jul 09, 2009 (Zacks.com via COMTEX) -- On July 7, GlaxoSmithKline Plc (GSK) announced that data from a large efficacy study showed that Cervarix, its human papillomavirus (HPV) vaccine, is [...]

Published
2009

32. Gardasil, Cervarix: not interchangeable

Author

Pichichero, Michael E.

Subjects
Cervarix (Vaccine), Cancer vaccines, Cervical cancer, Papillomavirus infections, Cancer prevention, Cancer -- Prevention
Abstract

With the licensure of GlaxoSmithKline's human papillomavirus vaccine Cervarix in October, we will soon have two vaccines that prevent cervical cancer in women. But they're not interchangeable, and this could [...]

Published
2009

33. Cervarix, Gardasil in science showdown

Author

Iskowitz, Marc

Subjects
Merck & Company Inc., Cervarix (Vaccine), Cancer vaccines, Cervical cancer, Papillomavirus infections, Pharmaceutical industry
Abstract

GLAXOSMITHKLINE'S FDA approval for Cervarix, received last month as rival Merck expanded its Gardasil label, heralds a market-share battle that may hinge on science. Cervarix is approved to protect women [...]

Published
2009

34. FDA approves Gardasil for boys and Cervarix for girls

Author

Farmer, Lori Buckner

Subjects
Merck & Company Inc., Cervarix (Vaccine), Papillomavirus infections, Pharmaceutical industry, Drug approval
Abstract

The Food and Drug Administration has approved the drug Gardasil for boys and men aged 926 years, and Cervarix for girls and women aged 10-25 years. Gardasil was approved for [...]

Published
2009

35. Cervarix found more immunogenic than gardasil

Author

Tucker, Miriam E.

Subjects
Merck & Company Inc., Cervarix (Vaccine), Vaccines, Papillomavirus infections, Pharmaceutical industry
Abstract

ATLANTA -- The efficacy of GlaxoSmithKline's human papillomavirus vaccine against cervical intraepithelial neoplasia grade 2 or higher was confirmed in a final analysis of phase III data from more than [...]

Published
2009

36. Cervarix is effective against CIN2+ lesions

Author

Tucker, Miriam E.

Subjects
Merck & Company Inc., Cervarix (Vaccine), Vaccines, Papillomavirus infections, Pharmaceutical industry
Abstract

ATLANTA -- The efficacy of GlaxoSmithKline's human papillomavirus vaccine against cervical intraepithelial neoplasia grade 2 or higher has been confirmed in a final analysis of phase III data from more [...]

Published
2009

37. Cervarix effective against CIN at 6-year follow-up

Author

Worcester, Sharon

Subjects
Cervarix (Vaccine), Vaccines, Papillomavirus infections, Medical research, Medicine, Experimental
Abstract

TAMPA -- The Cervarix vaccine provides protection for as long as 6.4 years against precancerous cervical lesions associated with the two most common cancer-causing types of human papillomavirus and substantial [...]

Published
2008

39. Fewer than 3 doses of cervical cancer vaccine effective

Subjects
Cervarix (Vaccine), Cancer treatment, Cancer vaccines, Cervical cancer, Papillomavirus infections, Cancer -- Care and treatment
Abstract

Fewer than three doses of the human papillomavirus (HPV) vaccine Cervarix may be just as effective as the standard three-dose regimen when it comes to preventive measures against cervical cancer, [...]

Published
2011

40. HPV: Fewer doses of Cervarix are as effective as three

Subjects
Cervarix (Vaccine), Vaccines, Papillomavirus infections
Abstract

One or two doses of the HPV vaccine Cervarix may be as effective in protecting against persistent HPV infections as the standard three-dose regimen. US researchers looked at data from [...]

Published
2011

41. GSK European Commission amends licence for Cervarix

Subjects
European Union. European Commission, Cervarix (Vaccine), Cancer treatment, Cancer vaccines, Cervical cancer, Papillomavirus infections, Pharmaceutical industry, Cancer -- Care and treatment
Abstract

London UK - GlaxoSmithKline (GSK) confirmed that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix® (see also Human Papillomavirus). The approval [...]

Published
2010

42. GlaxoSmithKline says European Commission amends licence for Cervarix

Subjects
Papillomavirus infections, Cervical cancer, Cancer vaccines, Pharmaceutical industry, Chemistry, European Union. European Commission, Cervarix (Vaccine)
Abstract

M2 PHARMA-August 25, 2010-GlaxoSmithKline says European Commission amends licence for Cervarix(C)2010 M2 COMMUNICATIONS 25 August 2010 - UK GlaxoSmithKline (LON: GSK) said yesterday that the European Commission has granted Marketing [...]

Published
2010

43. Landmark Study for GSK's Cervical Cancer Vaccine Published in the Lancet

Subjects
Cervarix (Vaccine), Diseases, Cancer treatment, Vaccines, Cervical cancer, Papillomavirus infections, Cancer research, Pharmaceutical industry, Oncology, Experimental, Cancer -- Care and treatment -- Research
Abstract

The final analysis of the largest efficacy trial of a cervical cancer vaccine is published in The Lancet. The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix(R) is highly effective at [...]

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results